SCT Plus Immune Therapy in Average Risk AML/MDS (NCT02117297)
Allogeneic stem cell transplantation followed by targeted immune therapy with the antibody-drug conjugate gemtuzumab ozogamicin (Mylotarg®; Pfizer/Wyeth-Ayerst Laboratories) will be given to patients with average risk AML or MDS.
This trial is sponsored by New York Medical College. 
- Acute Myelogenous Leukemia (AML)
- Myelodysplastic Syndrome (MDS)
- Phase: II
- Estimated Enrollment: 26
- Start: November 2011
- Estimated Completion: December 2018
- Last verified: January 2015
Last Editorial review: July 21, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.